$16.5m top-up propels Sutro's unnatural approach to biologics and drug conjugates
This article was originally published in Scrip
Sutro Biopharma closed the second tranche of a previously announced Series C funding round, bringing in $16.5 million in new cash to finance development of next-generation antibody-drug conjugates (ADCs) and complete renovations at a manufacturing facility for the San Francisco company's cell-free biochemical protein synthesis platform.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.